抗癌研究 Pub Date : 2023-07-27 DOI: 10.26689/par.v7i4.5152

Quan Shi

{"title":"The Effect of TSH Suppression Therapy on the Efficacy and Immune Function of Postoperative Patients with Thyroid Cancer","authors":"Quan Shi","doi":"10.26689/par.v7i4.5152","DOIUrl":"https://doi.org/10.26689/par.v7i4.5152","url":null,"abstract":"Objective: To investigate the efficacy and immune function of thyroid stimulating hormone (TSH) suppression therapy in postoperative thyroid cancer patients. Methods: Sixty thyroid cancer patients admitted from July 2020–July 2022 were recruited and randomly divided into two groups. The control group (30 patients) received hormone replacement therapy, while the study group (30 patients) received TSH suppression therapy. The thyroid function, clinical efficacy, immune function, and tumor markers of the two groups were compared. Results: After treatment, the levels of free triiodothyronine (FT3) and thyroxine (FT4) in both groups increased significantly, while TSH levels decreased significantly. Moreover, the magnitude of change in the study group was greater than that in the control group (P < 0.05). The total effective rate in the study group was significantly higher as compared to the control group (P < 0.05). After treatment, the levels of CD3+ and CD4+ cells in both groups of patients increased significantly, with the study group showing significantly higher levels than the control group, whereas the level of CD8+ cells decreased significantly, with the study group having lower levels than the control group (P < 0.05). After treatment, the levels of Tg and CEA in both groups were significantly lowered as compared to before treatment, and the levels of Tg and CEA in the study group were significantly lower than the control group (P < 0.05). Conclusion: TSH suppression therapy in postoperative thyroid cancer patients can improve thyroid function, suppress the levels of tumor markers, and enhance immune function, thereby achieving good clinical outcomes.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48881166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Diagnostic Value of Fecal Fusobacterium nucleatum Combined with FIT and CA199 in the Diagnosis of Colorectal Cancer 粪便有核梭杆菌联合FIT和CA199对癌症大肠癌的诊断价值

抗癌研究 Pub Date : 2023-07-27 DOI: 10.26689/par.v7i4.5129

Tianhong Jia, Yang Yu, Yan Wang, Ming Li, Shuzhuo Liu, Wei Li

{"title":"The Diagnostic Value of Fecal Fusobacterium nucleatum Combined with FIT and CA199 in the Diagnosis of Colorectal Cancer","authors":"Tianhong Jia, Yang Yu, Yan Wang, Ming Li, Shuzhuo Liu, Wei Li","doi":"10.26689/par.v7i4.5129","DOIUrl":"https://doi.org/10.26689/par.v7i4.5129","url":null,"abstract":"Objective: To analyze the diagnostic value of fecal Fusobacterium nucleatum detection, fecal immunochemical test (FIT), and carbohydrate antigen 19-9 (CA19-9) detection for colorectal cancer (CRC). Method: A total of 78 CRC patients and 60 healthy individuals were enrolled in this study. Stool and blood samples were collected for the 3 diagnoses, and ROC curves were analyzed for diagnostic value. Result: The 3 diagnoses’ positive detection rates in CRC samples were significantly higher than those of healthy samples (P < 0.05). The combined CRC diagnoses showed significantly higher sensitivity as compared to individual fecal F. nucleatum detection (χ2 = 6.495, P = 0.011), FIT (χ2 = 4.871, P = 0.027), and serum CA19-9 detection (χ2 = 7.371, P = 0.007). The area under the ROC curve for fecal F. nucleatum detection was 0.63 [95% confidence interval (CI) = 1.124–6.238], with a sensitivity of 73.08% and specificity of 85.00%, whereas FIT was 0.65 (95% CI = 1.365–9.241), with a sensitivity of 51.28% and specificity of 96.67%, meanwhile, serum CA19-9 detection was 0.62 (95% CI = 1.517–12.342), with a sensitivity of 69.23% and specificity of 98.33%. The combined CRC diagnoses showed an area under the ROC curve of 0.76 (95% CI = 1.213–6.254), with a sensitivity of 87.18% and specificity of 70.00%. Conclusion: The combined diagnoses of fecal F. nucleatum detection, FIT, and serum CA19-9 detection can significantly improve the sensitivity and accuracy of CRC diagnosis, which has high clinical application value to provide guidance for clinical CRC screening and early intervention treatment.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49255181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Value of cfDNA Content in Peripheral Blood of Patients with Triple-Negative Breast Cancer 三阴性乳腺癌患者外周血cfDNA含量的临床价值

抗癌研究 Pub Date : 2023-07-25 DOI: 10.26689/par.v7i4.5179

Jirui Sun, Qiushuang Ma, Huifen. Chen, Xing Zhou, Bi-Yun Zhou, Jinku Zhang

{"title":"Clinical Value of cfDNA Content in Peripheral Blood of Patients with Triple-Negative Breast Cancer","authors":"Jirui Sun, Qiushuang Ma, Huifen. Chen, Xing Zhou, Bi-Yun Zhou, Jinku Zhang","doi":"10.26689/par.v7i4.5179","DOIUrl":"https://doi.org/10.26689/par.v7i4.5179","url":null,"abstract":"Objective: To explore the value of circulating free (cfDNA) content in the clinical diagnosis and treatment of triple-negative breast cancer (TNBC). Methods: A total of 39 TNBC patients, 45 non-TNBC patients, and 50 healthy individuals admitted to the Baoding First Central Hospital during 2019–2022 were recruited. The clinical data, peripheral blood cfDNA concentration, and clinicopathological indicators of the patients were observed and analyzed. Results: The difference in clinical indicators such as age, age range, tumor size, clinical stage, and lymph node metastasis between patients with TNBC and non-TNBC was insignificant (P > 0.05). The cfDNA concentrations (ng/mL) of the TNBC group, non-TNBC group, and healthy group were 24.12 ± 4.98, 15.36 ± 4.12, and 3.12 ± 1.02, respectively, and they are statistically different (P < 0.05). The difference in cfDNA concentration was insignificant between TNBC patients with tumors ≤ 2 cm and > 2 cm (P > 0.05) but was significant between TNBC patients with clinical stages I+II and III+IV (P < 0.05). The cfDNA concentration in TNBC patients with lymph node metastasis was significantly higher than those without lymph node metastasis (P < 0.05). Conclusion: cfDNA has an important application value in the diagnosis and treatment of breast cancer. By detecting the cfDNA level and its gene variation, valuable information about the progress and treatment effects of breast cancer can be obtained. This non-invasive detection method has a wide range of applications and can be used for early screening, auxiliary diagnosis, efficacy evaluation, and recurrence monitoring of breast cancer.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49105130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Study on Yeast Using the Photoreactivation Process to Repair the Pyrimidine Dimer Mutations 酵母光活化修复嘧啶二聚体突变的研究

抗癌研究 Pub Date : 2023-07-25 DOI: 10.26689/par.v7i4.5191

Yichen Liu

引用次数: 0

Efficacy of Low-Dose Rituximab in Primary Immune Thrombocytopenia 小剂量利妥昔单抗治疗原发性免疫性血小板减少症的疗效

抗癌研究 Pub Date : 2023-07-20 DOI: 10.26689/par.v7i4.5153

Ben Niu, Lan Li

{"title":"Efficacy of Low-Dose Rituximab in Primary Immune Thrombocytopenia","authors":"Ben Niu, Lan Li","doi":"10.26689/par.v7i4.5153","DOIUrl":"https://doi.org/10.26689/par.v7i4.5153","url":null,"abstract":"Objective: To explore the effect of low-dose rituximab in primary immune thrombocytopenia. Methods: From January 2022 to January 2023, 60 patients with primary immune thrombocytopenia were randomly divided into two groups. The control group was treated with standard doses of rituximab, and the observation group was treated with low doses of rituximab. Rituximab was used for treatment, and the clinical curative effect of the two groups was observed. Results: Before treatment, there was no statistically significant difference in platelet count (PLT), anti-GPⅡb/Ⅲa antibody, and anti-GPⅠb/Ⅸ antibody between the two groups (P > 0.05). After treatment, the PLT of the two groups increased significantly. Antibodies were all decreased, and there was no significant difference between the two groups (P > 0.05). The incidence of adverse reactions in the observation group was 13.33%, and that in the control group was 40.00%. The adverse reactions in the observation group were significantly lower than the control group (P < 0.05). Conclusion: In the clinical treatment of primary immune thrombocytopenia, low-dose rituximab can control the progression of the disease, improve blood routine indicators, and have fewer adverse reactions.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44037317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of IL-6/JAK2/STAT3 on the Biological Behavior of Oral Squamous Cell Carcinoma IL-6/JAK2/STAT3对口腔鳞状细胞癌生物学行为的影响

抗癌研究 Pub Date : 2023-07-20 DOI: 10.26689/par.v7i4.5084

Yan Hu, Zhizheng Zhuang, Hongyue Liu

{"title":"Effects of IL-6/JAK2/STAT3 on the Biological Behavior of Oral Squamous Cell Carcinoma","authors":"Yan Hu, Zhizheng Zhuang, Hongyue Liu","doi":"10.26689/par.v7i4.5084","DOIUrl":"https://doi.org/10.26689/par.v7i4.5084","url":null,"abstract":"Objective: To investigate the effect of interleukin 6/Janus kinase 2/signal transducer and activator of transcription 3 (IL-6/JAK2/STAT3) on the biological behavior of oral squamous cell carcinoma (OSCC). Methods: OSCC cells were transfected with the designed lentiviral vector plasmid pGMLV-SB3 (experimental group) and the corresponding negative control plasmid pGMLV-SB3-shNC (control group); 48 hours after transfection, a liposome transfection kit (Sigma, USA) was used for lentivirus packaging; after virus packaging, a medium containing pGMLV-SB3 lentiviral vector was added and cultured for 24 h; the cells were harvested, and RNA was extracted; Transwell chamber assay (Sigma, USA) was used to detect cell migration and invasion ability; dot-enzyme-linked immunosorbent assay (ELISA) kit was used to detect the level of interleukin 6 (IL-6) in the culture supernatant, while serum IL-6 level was measured by ELISA. Results: The expressions of IL-6, JAK2, and STAT3 in the experimental group were significantly raised, as compared to the control group (P < 0.05); the apoptosis rate of OSCC cells in the experimental group, which was detected by flow cytometry 48 h after transfection, was significantly higher than that of cells in the control group (P < 0.05); and there was a significant improvement in the experimental group’s cell migration and invasion ability, as compared to that of the control group (P < 0.05). Conclusion: The IL-6/JAK2/STAT3 signaling pathway plays an important role in the migration and invasion of OSCC cells. Inhibiting the expression of IL-6 can inhibit the growth and proliferation of OSCC cells as well as reduce their ability to invade and migrate. These results provide a new target for the treatment of OSCC.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46616284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Value of Hepatitis B Virus RNA Detection in Patients with Chronic Hepatitis B Infection 慢性乙型肝炎患者乙型肝炎病毒RNA检测的临床价值

抗癌研究 Pub Date : 2023-07-18 DOI: 10.26689/par.v7i4.4919

Yu Li, YF Lyu, F. Xi

引用次数: 0

Successful Treatment of White Lung in Elderly Patients with COVID-19 老年COVID-19患者白肺的成功治疗

抗癌研究 Pub Date : 2023-07-11 DOI: 10.26689/par.v7i4.5136

Chao Fang, Nuan Xiao, Shengnan Huang, Jiannan Wu, Lili Tan, Hongmei Zhao

引用次数: 0

Biosynthesis and Characterization of Silver Nanoparticles Coated with Metabolites Extracted from Clerodendron phlomoides with Its Biochemical Studies in Liver Tissue 绿枝棘叶代谢物包被银纳米粒子的生物合成、表征及肝组织生化研究

抗癌研究 Pub Date : 2023-07-05 DOI: 10.26689/par.v7i4.5049

Subha Veeramani, K. Shanmugam

{"title":"Biosynthesis and Characterization of Silver Nanoparticles Coated with Metabolites Extracted from Clerodendron phlomoides with Its Biochemical Studies in Liver Tissue","authors":"Subha Veeramani, K. Shanmugam","doi":"10.26689/par.v7i4.5049","DOIUrl":"https://doi.org/10.26689/par.v7i4.5049","url":null,"abstract":"Silver nanoparticles (AgNPs) have been used as a potential nanomaterial-based drug delivery vehicle for liver cancer treatment, as it induces cell death and produces cytotoxicity against cancerous cells at a low concentration. The biosynthesis of green metallic nanoparticles uses secondary metabolites in plant extracts instead of toxic chemicals for a reduction-oxidation (redox) reaction. The biosynthesis of AgNPs with the aqueous extract of Clerodendron phlomoides was performed in this study. The phytochemical analysis of C. phlomoides extract using gas chromatography-mass spectrometry (GC-MS) confirmed the presence of redox metabolites. The peak at 489 nm in UV-visible spectra confirmed the formation of bioactive AgNPs reduced from silver nitrate solution, whereas the Fourier-transform infrared (FTIR) spectra indicated the bioactive molecules of plant extracts that are responsible for the formation. Scanning electron microscope (SEM) micrograph revealed the formation of spherical and ovoid structures of AgNPs, whereas transmission electron microscope (TEM) micrograph confirmed the size of AgNPs, which varies from 25 nm to 100 nm. X-ray diffraction (XRD) spectra showed the crystalline nature of AgNPs, and the size of crystallite was 4 nm, while dynamic light scattering (DLS) analysis confirmed the average particle size of AgNPs to be around 125 nm. In vivo studies showed that bioactive AgNPs have a significant anticancer potential against liver cancer, whereas biochemical studies of rats’ liver tissue samples confirmed that bioactive AgNPs produced a potential hepatoprotective effect against diethylnitrosamine-induced liver cancer.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48233803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance Evaluation of Combined Detection of Serum CEA, CYFRA21-1, CA125, and NSE in Patients with Lung Cancer by Fluorescence Flow Cytometry 荧光流式细胞术联合检测癌症患者血清CEA、CYFRA21-1、CA125和NSE的疗效评价

抗癌研究 Pub Date : 2023-05-30 DOI: 10.26689/par.v7i3.4850

Xiaoxue Huang, Xiaomeng Zheng, Yiyang Li, L. Duan, Yang Yu

{"title":"Performance Evaluation of Combined Detection of Serum CEA, CYFRA21-1, CA125, and NSE in Patients with Lung Cancer by Fluorescence Flow Cytometry","authors":"Xiaoxue Huang, Xiaomeng Zheng, Yiyang Li, L. Duan, Yang Yu","doi":"10.26689/par.v7i3.4850","DOIUrl":"https://doi.org/10.26689/par.v7i3.4850","url":null,"abstract":"Objective: To investigate the effect of combined detection of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), cancer antigen 125 (CA125), and neuron-specific enolase (NSE) in patients with lung cancer by fluorescence flow cytometry. Methods: From August 2019 to July 2022, 200 patients with lung cancer diagnosed by pathology in our hospital were retrospectively analyzed. 2 mL venous blood was collected in a fasting state and centrifuged to separate the serum (containing human chorionic gonadotropin antibody [anti-hCG antibody], hepatitis B surface antibody [anti-HBs antibody], and CEA). Results: The sensitivities of CEA and CYFRA21-1 detected via enzyme-linked immunosorbent assay (ELISA) were 100%, and the detection limits were 0.5 ng/mL and 0.1 ng/mL, respectively; the sensitivities of CA125 and NSE detected via flow cytometry were 100%, and the detection limits were 10 U/mL and 2 ng/mL, respectively. Compared with ELISA, the sensitivities of CA125 and NSE detected via flow cytometry were higher. When the concentration of CEA was 10–40 ng/mL, the sensitivities of the three markers CYFRA21-1, CA125, and NSE showed no significant changes (P > 0.05); when the concentration of CEA was 40–80 ng/mL, the sensitivity of CEA significantly decreased (P < 0.01), but the sensitivities of the three markers CYFRA21-1, CA125, and NSE showed no significant changes (P > 0.05); when the concentration of CEA was 80–200 ng/mL, the sensitivities of all four markers showed no significant changes (P > 0.05). Conclusion: Compared with the double-antibody sandwich ELISA, fluorescence flow cytometry has certain advantages, including high sensitivity, good precision, short detection time, low sample usage, and low medical cost; thus, it is worthy of clinical promotion.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42980520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

抗癌研究最新文献